ABVC BioPharma Strengthens Ophthalmology Portfolio with $100,000 Milestone Payment from ForSeeCon
TL;DR
ABVC BioPharma's partnership with ForSeeCon enhances its position in the $110B global eye care market, offering potential billion-dollar returns through innovative ophthalmic solutions like Vitargus®.
ABVC BioPharma's licensing agreement with ForSeeCon involves milestone payments totaling $946,000, aiming to develop Vitargus® for pivotal clinical trials in key international markets by 2025.
ABVC BioPharma and ForSeeCon's collaboration on Vitargus® aims to improve retinal surgery outcomes, addressing unmet needs in ophthalmology and enhancing global eye care.
ABVC BioPharma's Vitargus®, a next-generation vitreous substitute, is gaining international interest, with potential to revolutionize eye care and foster global partnerships in Europe and Japan.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the receipt of a $100,000 milestone licensing payment from ForSeeCon Eye Corporation, marking a significant step in their partnership to develop and commercialize drugs for ophthalmic indications. This payment brings ABVC’s cumulative licensing revenue to $946,000, with the potential for the overall value of their agreements to reach up to $1.0 billion. The collaboration focuses on Vitargus®, a next-generation vitreous substitute, targeting the rapidly expanding $110 billion global eye care market.
Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the importance of this milestone payment as a reflection of commercial interest in their platform and a source of non-dilutive capital for future development phases. The enthusiasm for Vitargus® from international partners, especially in Europe and Japan, suggests promising opportunities for strategic collaborations in these regions. Mr. Jerry Chang, CEO of ForSeeCon Eye Corporation, shared his optimism about the global response to Vitargus® and its potential to improve retinal surgery outcomes.
The partnership between ABVC and ForSeeCon is set to initiate pivotal clinical trials in key international markets in 2025, further solidifying ABVC’s position in the ophthalmology sector. According to a report by Grand View Research, the global eye care market is projected to reach USD 110.3 billion by 2030, growing at a compound annual growth rate of 6.9% from 2024 to 2030. This growth underscores the significant market potential for ABVC’s product pipeline, including Vitargus®.
ABVC’s strategic roadmap is supported by this latest payment, reflecting momentum from multiple late-stage CNS licensing deals and expansion into oncology. With licensing income expected to continue into the second half of 2025, ABVC remains focused on capital-efficient innovation and unlocking value through global co-development partnerships. The company’s commitment to addressing unmet needs in ophthalmology through advanced biologic solutions like Vitargus® positions it as a key player in the evolving eye care market.
Curated from NewMediaWire
